Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).

Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana.

Brovana® is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for:

According to IQVIA (IMS Health), Brovana had US sales of approximately $438M for the 12-month period ending April 2021.

The product is available for shipping immediately.